// App-Quantinova.ai

: Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study

Researchers

Presenter

  • Jennifer R. Brown

Principal Investigators

  • Matthew S. Davids

  • Peter Hillmen

  • Marco Montillo

  • Zsolt Nagy

  • Julio Delgado

  • Bryone J. Kuss

  • Constantine S. Tam

  • Ulrich Jaeger

  • Paolo Ghia

  • Stephan Stilgenbauer

  • Carol Moreno

  • NgocDiep Le

  • Stephanie Lustgarten

  • Kam Sprott

  • Jonathan A. Pachter

  • David T. Weaver

  • Florence Cymbalista

Medical Centers

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • St. James's University Hospital, Leeds, United Kingdom

  • Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy

  • First Department of Internal Medicine, Semmelweis University, Budapest, Hungary

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Flinders Medical Centre—Flinders University,Bedford Park, SA,Australia

  • Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, Melbourne, Victoria, Australia

  • Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria

  • Universita Vita-Salute San Raffaele and IRCCS Instituto Scientifico San Raffaele, Milano, Italy

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Innere Medizin I, Universitaetsklinikum des Saarlandes, Homburg/Saar, Germany

  • Hospital De La Santa Creu I Sant Pau, Barcelona, ESP

  • Verastem Oncology, Needham, MA

  • Laboratoire -Hematologie Biologique, Hopital Avicenne, Bobigny, France

Locations

  • United States

  • United Kingdom

  • Italy

  • Hungary

  • Spain

  • Australia

  • Austria

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Duvelisib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02004522

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved